Your browser doesn't support javascript.
loading
Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome.
Dutta, Tanmoy; Sasidharan, Kavitha; Ciociola, Ester; Pennisi, Grazia; Noto, Francesca R; Kovooru, Lohitesh; Kroon, Tobias; Lindblom, Anna; Du, Yue; Pirmoradian, Mohammad; Wallin, Simonetta; Mancina, Rosellina M; Lindén, Daniel; Romeo, Stefano.
Afiliación
  • Dutta T; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Sasidharan K; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Ciociola E; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Pennisi G; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Noto FR; Section of Gastroenterology and Hepatology, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica Di Eccellenza (PROMISE), University of Palermo, Palermo, Italy.
  • Kovooru L; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Kroon T; Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.
  • Lindblom A; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
  • Du Y; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Pirmoradian M; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Wallin S; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Mancina RM; Translational Science and Experimental Medicine, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lindén D; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Romeo S; Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
Liver Int ; 44(5): 1219-1232, 2024 05.
Article en En | MEDLINE | ID: mdl-38375985
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oxidorreductasas / Proteínas Mitocondriales / Complejo de la Endopetidasa Proteasomal / Hígado Graso Límite: Animals / Humans Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oxidorreductasas / Proteínas Mitocondriales / Complejo de la Endopetidasa Proteasomal / Hígado Graso Límite: Animals / Humans Idioma: En Revista: Liver Int Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Suecia